(27/05/2020, 09:57)Zefiris Escreveu: Se é para falar de ganho das industrias farmaceuticas, elas devem ganhar mais fazendo lobby contra a cloroquina que é um remédio muito barato, ao contrário de uns por aí.
E OMS não é parâmetro, pois só ver o discurso dela no começo do ano que deixa óbvio seu viés politico. O próprio Japão reclamou dela.
OMS se baseou em um estudo que saiu na the lancet revista muito conceituada do ramo de medicina em um estudo de larga escala.
OMS com certeza não é confiável por ter escondido a pandemia no começo com a China, mas não é a voz da OMS que está afirmando mas uma revista da area, depois confirmo se é esse texto mesmo:
https://www.thelancet.com/journals/lance...6/fulltext
DiscussionIn this large multinational real-world analysis, we did not observe any benefit of hydroxychloroquine or chloroquine (when used alone or in combination with a macrolide) on in-hospital outcomes, when initiated early after diagnosis of COVID-19. Each of the drug regimens of chloroquine or hydroxychloroquine alone or in combination with a macrolide was associated with an increased hazard for clinically significant occurrence of ventricular arrhythmias and increased risk of in-hospital death with COVID-19.
The use of hydroxychloroquine or chloroquine in COVID-19 is based on widespread publicity of small, uncontrolled studies, which suggested that the combination of hydroxychloroquine with the macrolide azithromycin was successful in clearing viral replication.
7
On March 28, 2020, the FDA issued an emergency use authorisation for these drugs in patients if clinical trial access was unavailable.
12
Other countries, such as China, have issued guidelines allowing for the use of chloroquine in COVID-19.
13
Several countries have been stockpiling the drugs, and shortages of them for approved indications, such as for autoimmune disease and rheumatoid arthritis, have been encountered.
10
A retrospective observational review of 368 men with COVID-19 treated at the US Veterans Affairs hospitals raised concerns that the use of hydroxychloroquine was associated with a greater hazard of death; however, the baseline characteristics among the groups analysed were dissimilar and the possibility of bias cannot be ruled out.
14
Another observational study in 181 patients from France reported that the use of hydroxychloroquine at a dose of 600 mg per day was not associated with a measurable clinical benefit in patients with COVID-19 pneumonia.
15
Our large-scale, international, real-world analysis supports the absence of a clinical benefit of chloroquine and hydroxychloroquine and points to potential harm in hospitalised patients with COVID-19.
já que são cidades top 3 de mortes covid.
